 | • レポートコード：GIR201105761 • 出版社/出版日：GlobalInfoResearch / 2020年10月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、133ページ • 納品方法：Eメール • 産業分類：医薬品・医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本書では、神経内分泌腫瘍治療薬の世界市場を調査対象にし、神経内分泌腫瘍治療薬の市場概要、メーカー情報、メーカー別販売量・売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（mTORタンパク質阻害剤、チロシンキナーゼ3阻害剤、ソマトスタチン受容体拮抗薬、成長ホルモン放出因子拮抗薬、ソマトスタチン受容体作動薬、その他）、用途別分析（病院、クリニック、その他）、市場予測（2021年～2025年）、販売チャンネル・代理店分析情報などを整理しました。 ・市場概要 ・メーカー情報：Eisai、Jiangsu Hengrui Medicine Co., Ltd.、Hutchison MediPharma Limited、Exelixis, Inc.、Ipsen S.A.、Foresee Pharmaceuticals, LLC、Lexicon Pharmaceuticals, Inc.、INVENT Pharmaceuticals, Inc.、Intezyne, Inc、Karyopharm Therapeutics, Inc.、Novartis AG、Midatech Pharma Plc .、OctreoPharm Sciences GmbH、Northwest Biotherapeutics, Inc.、Millennium Pharmaceuticals, Inc.、OXiGENE, Inc.、MolMed S.p.A. ・メーカー別販売量、売上、市場シェア ・神経内分泌腫瘍治療薬の地域別市場分析 ・神経内分泌腫瘍治療薬の北米市場規模2015-2020：アメリカ、カナダ、メキシコ ・神経内分泌腫瘍治療薬のヨーロッパ市場規模2015-2020：ドイツ、イギリス、フランス、ロシアなど ・神経内分泌腫瘍治療薬のアジア市場規模2015-2020：日本、中国、韓国、インド、東南アジアなど ・神経内分泌腫瘍治療薬の南米市場規模2015-2020：ブラジル、アルゼンチンなど ・神経内分泌腫瘍治療薬の中東・アフリカ市場規模2015-2020：サウジアラビア、トルコ、エジプト、南アフリカなど ・神経内分泌腫瘍治療薬の種類別市場規模2015-2020：mTORタンパク質阻害剤、チロシンキナーゼ3阻害剤、ソマトスタチン受容体拮抗薬、成長ホルモン放出因子拮抗薬、ソマトスタチン受容体作動薬、その他 ・神経内分泌腫瘍治療薬の用途別市場規模2015-2020：病院、クリニック、その他 ・神経内分泌腫瘍治療薬の世界市場予測2021-2025：地域別、種類別、用途別 ・販売チャンネル・代理店分析 ・調査の結果・結論 |
Market Overview
The global Neuroendocrine Tumor Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Neuroendocrine Tumor Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Neuroendocrine Tumor Drug market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Neuroendocrine Tumor Drug market has been segmented into
mTOR protein inhibitors
Tyrosine kinase 3 inhibitors
Somatostatin receptor antagonists
Growth hormone releasing factor antagonists
Somatostatin receptor agonists
Others
By Application, Neuroendocrine Tumor Drug has been segmented into:
Hospital
Clinic
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Neuroendocrine Tumor Drug market presented in the report. This section sheds light on the sales growth of different regional and country-level Neuroendocrine Tumor Drug markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Neuroendocrine Tumor Drug market.
The report offers in-depth assessment of the growth and other aspects of the Neuroendocrine Tumor Drug market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Neuroendocrine Tumor Drug Market Share Analysis
Neuroendocrine Tumor Drug competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Neuroendocrine Tumor Drug sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Neuroendocrine Tumor Drug sales, revenue and market share for each player covered in this report.
The major players covered in Neuroendocrine Tumor Drug are:
Eisai
Jiangsu Hengrui Medicine Co., Ltd.
Hutchison MediPharma Limited
Exelixis, Inc.
Ipsen S.A.
Foresee Pharmaceuticals, LLC
Lexicon Pharmaceuticals, Inc.
INVENT Pharmaceuticals, Inc.
Intezyne, Inc
Karyopharm Therapeutics, Inc.
Novartis AG
Midatech Pharma Plc .
OctreoPharm Sciences GmbH
Northwest Biotherapeutics, Inc.
Millennium Pharmaceuticals, Inc.
OXiGENE, Inc.
MolMed S.p.A.
Among other players domestic and global, Neuroendocrine Tumor Drug market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Neuroendocrine Tumor Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Neuroendocrine Tumor Drug, with price, sales, revenue and global market share of Neuroendocrine Tumor Drug in 2018 and 2019.
Chapter 3, the Neuroendocrine Tumor Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neuroendocrine Tumor Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Neuroendocrine Tumor Drug market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Neuroendocrine Tumor Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Neuroendocrine Tumor Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Neuroendocrine Tumor Drug Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 mTOR protein inhibitors
1.2.3 Tyrosine kinase 3 inhibitors
1.2.4 Somatostatin receptor antagonists
1.2.5 Growth hormone releasing factor antagonists
1.2.6 Somatostatin receptor agonists
1.2.7 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Neuroendocrine Tumor Drug Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Overview of Global Neuroendocrine Tumor Drug Market
1.4.1 Global Neuroendocrine Tumor Drug Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Eisai
2.1.1 Eisai Details
2.1.2 Eisai Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Eisai SWOT Analysis
2.1.4 Eisai Product and Services
2.1.5 Eisai Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Jiangsu Hengrui Medicine Co., Ltd.
2.2.1 Jiangsu Hengrui Medicine Co., Ltd. Details
2.2.2 Jiangsu Hengrui Medicine Co., Ltd. Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Jiangsu Hengrui Medicine Co., Ltd. SWOT Analysis
2.2.4 Jiangsu Hengrui Medicine Co., Ltd. Product and Services
2.2.5 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Hutchison MediPharma Limited
2.3.1 Hutchison MediPharma Limited Details
2.3.2 Hutchison MediPharma Limited Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Hutchison MediPharma Limited SWOT Analysis
2.3.4 Hutchison MediPharma Limited Product and Services
2.3.5 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Exelixis, Inc.
2.4.1 Exelixis, Inc. Details
2.4.2 Exelixis, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Exelixis, Inc. SWOT Analysis
2.4.4 Exelixis, Inc. Product and Services
2.4.5 Exelixis, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Ipsen S.A.
2.5.1 Ipsen S.A. Details
2.5.2 Ipsen S.A. Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Ipsen S.A. SWOT Analysis
2.5.4 Ipsen S.A. Product and Services
2.5.5 Ipsen S.A. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Foresee Pharmaceuticals, LLC
2.6.1 Foresee Pharmaceuticals, LLC Details
2.6.2 Foresee Pharmaceuticals, LLC Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Foresee Pharmaceuticals, LLC SWOT Analysis
2.6.4 Foresee Pharmaceuticals, LLC Product and Services
2.6.5 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Lexicon Pharmaceuticals, Inc.
2.7.1 Lexicon Pharmaceuticals, Inc. Details
2.7.2 Lexicon Pharmaceuticals, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Lexicon Pharmaceuticals, Inc. SWOT Analysis
2.7.4 Lexicon Pharmaceuticals, Inc. Product and Services
2.7.5 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 INVENT Pharmaceuticals, Inc.
2.8.1 INVENT Pharmaceuticals, Inc. Details
2.8.2 INVENT Pharmaceuticals, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 INVENT Pharmaceuticals, Inc. SWOT Analysis
2.8.4 INVENT Pharmaceuticals, Inc. Product and Services
2.8.5 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 Intezyne, Inc
2.9.1 Intezyne, Inc Details
2.9.2 Intezyne, Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Intezyne, Inc SWOT Analysis
2.9.4 Intezyne, Inc Product and Services
2.9.5 Intezyne, Inc Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 Karyopharm Therapeutics, Inc.
2.10.1 Karyopharm Therapeutics, Inc. Details
2.10.2 Karyopharm Therapeutics, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Karyopharm Therapeutics, Inc. SWOT Analysis
2.10.4 Karyopharm Therapeutics, Inc. Product and Services
2.10.5 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.11 Novartis AG
2.11.1 Novartis AG Details
2.11.2 Novartis AG Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Novartis AG SWOT Analysis
2.11.4 Novartis AG Product and Services
2.11.5 Novartis AG Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.12 Midatech Pharma Plc .
2.12.1 Midatech Pharma Plc . Details
2.12.2 Midatech Pharma Plc . Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Midatech Pharma Plc . SWOT Analysis
2.12.4 Midatech Pharma Plc . Product and Services
2.12.5 Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.13 OctreoPharm Sciences GmbH
2.13.1 OctreoPharm Sciences GmbH Details
2.13.2 OctreoPharm Sciences GmbH Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 OctreoPharm Sciences GmbH SWOT Analysis
2.13.4 OctreoPharm Sciences GmbH Product and Services
2.13.5 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.14 Northwest Biotherapeutics, Inc.
2.14.1 Northwest Biotherapeutics, Inc. Details
2.14.2 Northwest Biotherapeutics, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Northwest Biotherapeutics, Inc. SWOT Analysis
2.14.4 Northwest Biotherapeutics, Inc. Product and Services
2.14.5 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.15 Millennium Pharmaceuticals, Inc.
2.15.1 Millennium Pharmaceuticals, Inc. Details
2.15.2 Millennium Pharmaceuticals, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Millennium Pharmaceuticals, Inc. SWOT Analysis
2.15.4 Millennium Pharmaceuticals, Inc. Product and Services
2.15.5 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.16 OXiGENE, Inc.
2.16.1 OXiGENE, Inc. Details
2.16.2 OXiGENE, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 OXiGENE, Inc. SWOT Analysis
2.16.4 OXiGENE, Inc. Product and Services
2.16.5 OXiGENE, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.17 MolMed S.p.A.
2.17.1 MolMed S.p.A. Details
2.17.2 MolMed S.p.A. Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 MolMed S.p.A. SWOT Analysis
2.17.4 MolMed S.p.A. Product and Services
2.17.5 MolMed S.p.A. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Neuroendocrine Tumor Drug Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Neuroendocrine Tumor Drug Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Neuroendocrine Tumor Drug Manufacturer Market Share in 2019
3.3.2 Top 6 Neuroendocrine Tumor Drug Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Neuroendocrine Tumor Drug Sales, Revenue and Market Share by Regions
4.1.1 Global Neuroendocrine Tumor Drug Sales and Market Share by Regions (2015-2020)
4.1.2 Global Neuroendocrine Tumor Drug Revenue and Market Share by Regions (2015-2020)
4.2 North America Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
4.3 Europe Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
4.5 South America Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Neuroendocrine Tumor Drug Sales, Revenue and Market Share by Country
5.1.1 North America Neuroendocrine Tumor Drug Sales and Market Share by Country (2015-2020)
5.1.2 North America Neuroendocrine Tumor Drug Revenue and Market Share by Country (2015-2020)
5.2 United States Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
5.3 Canada Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
5.4 Mexico Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Neuroendocrine Tumor Drug Sales, Revenue and Market Share by Country
6.1.1 Europe Neuroendocrine Tumor Drug Sales and Market Share by Country (2015-2020)
6.1.2 Europe Neuroendocrine Tumor Drug Revenue and Market Share by Country (2015-2020)
6.2 Germany Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
6.3 UK Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
6.4 France Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
6.5 Russia Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
6.6 Italy Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Neuroendocrine Tumor Drug Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Neuroendocrine Tumor Drug Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Neuroendocrine Tumor Drug Revenue and Market Share by Regions (2015-2020)
7.2 China Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
7.3 Japan Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
7.4 Korea Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
7.5 India Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
7.7 Australia Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Neuroendocrine Tumor Drug Sales, Revenue and Market Share by Country
8.1.1 South America Neuroendocrine Tumor Drug Sales and Market Share by Country (2015-2020)
8.1.2 South America Neuroendocrine Tumor Drug Revenue and Market Share by Country (2015-2020)
8.2 Brazil Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
8.3 Argentina Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Neuroendocrine Tumor Drug Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Neuroendocrine Tumor Drug Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Neuroendocrine Tumor Drug Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
9.3 Turkey Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
9.4 Egypt Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
9.5 South Africa Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Neuroendocrine Tumor Drug Sales and Market Share by Type (2015-2020)
10.2 Global Neuroendocrine Tumor Drug Revenue and Market Share by Type (2015-2020)
10.3 Global Neuroendocrine Tumor Drug Price by Type (2015-2020)
11 Global Neuroendocrine Tumor Drug Market Segment by Application
11.1 Global Neuroendocrine Tumor Drug Sales Market Share by Application (2015-2020)
11.2 Global Neuroendocrine Tumor Drug Revenue Market Share by Application (2015-2020)
11.3 Global Neuroendocrine Tumor Drug Price by Application (2015-2020)
12 Market Forecast
12.1 Global Neuroendocrine Tumor Drug Sales, Revenue and Growth Rate (2021-2025)
12.2 Neuroendocrine Tumor Drug Market Forecast by Regions (2021-2025)
12.2.1 North America Neuroendocrine Tumor Drug Market Forecast (2021-2025)
12.2.2 Europe Neuroendocrine Tumor Drug Market Forecast (2021-2025)
12.2.3 Asia-Pacific Neuroendocrine Tumor Drug Market Forecast (2021-2025)
12.2.4 South America Neuroendocrine Tumor Drug Market Forecast (2021-2025)
12.2.5 Middle East & Africa Neuroendocrine Tumor Drug Market Forecast (2021-2025)
12.3 Neuroendocrine Tumor Drug Market Forecast by Type (2021-2025)
12.3.1 Global Neuroendocrine Tumor Drug Sales Forecast by Type (2021-2025)
12.3.2 Global Neuroendocrine Tumor Drug Market Share Forecast by Type (2021-2025)
12.4 Neuroendocrine Tumor Drug Market Forecast by Application (2021-2025)
12.4.1 Global Neuroendocrine Tumor Drug Sales Forecast by Application (2021-2025)
12.4.2 Global Neuroendocrine Tumor Drug Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Neuroendocrine Tumor Drug Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Neuroendocrine Tumor Drug by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Neuroendocrine Tumor Drug Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Eisai Basic Information, Manufacturing Base and Competitors
Table 8. Eisai Neuroendocrine Tumor Drug Major Business
Table 9. Eisai Neuroendocrine Tumor Drug Total Revenue (USD Million) (2018-2019)
Table 10. Eisai SWOT Analysis
Table 11. Eisai Neuroendocrine Tumor Drug Product and Services
Table 12. Eisai Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Jiangsu Hengrui Medicine Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 14. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Major Business
Table 15. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Total Revenue (USD Million) (2018-2019)
Table 16. Jiangsu Hengrui Medicine Co., Ltd. SWOT Analysis
Table 17. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product and Services
Table 18. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Hutchison MediPharma Limited Basic Information, Manufacturing Base and Competitors
Table 20. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Major Business
Table 21. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Total Revenue (USD Million) (2018-2019)
Table 22. Hutchison MediPharma Limited SWOT Analysis
Table 23. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product and Services
Table 24. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Exelixis, Inc. Basic Information, Manufacturing Base and Competitors
Table 26. Exelixis, Inc. Neuroendocrine Tumor Drug Major Business
Table 27. Exelixis, Inc. Neuroendocrine Tumor Drug Total Revenue (USD Million) (2018-2019)
Table 28. Exelixis, Inc. SWOT Analysis
Table 29. Exelixis, Inc. Neuroendocrine Tumor Drug Product and Services
Table 30. Exelixis, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Ipsen S.A. Basic Information, Manufacturing Base and Competitors
Table 32. Ipsen S.A. Neuroendocrine Tumor Drug Major Business
Table 33. Ipsen S.A. Neuroendocrine Tumor Drug Total Revenue (USD Million) (2018-2019)
Table 34. Ipsen S.A. SWOT Analysis
Table 35. Ipsen S.A. Neuroendocrine Tumor Drug Product and Services
Table 36. Ipsen S.A. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Foresee Pharmaceuticals, LLC Basic Information, Manufacturing Base and Competitors
Table 38. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Major Business
Table 39. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Total Revenue (USD Million) (2018-2019)
Table 40. Foresee Pharmaceuticals, LLC SWOT Analysis
Table 41. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product and Services
Table 42. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Lexicon Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 44. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Major Business
Table 45. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Total Revenue (USD Million) (2018-2019)
Table 46. Lexicon Pharmaceuticals, Inc. SWOT Analysis
Table 47. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product and Services
Table 48. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. INVENT Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 50. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Major Business
Table 51. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Total Revenue (USD Million) (2018-2019)
Table 52. INVENT Pharmaceuticals, Inc. SWOT Analysis
Table 53. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product and Services
Table 54. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. Intezyne, Inc Basic Information, Manufacturing Base and Competitors
Table 56. Intezyne, Inc Neuroendocrine Tumor Drug Major Business
Table 57. Intezyne, Inc Neuroendocrine Tumor Drug Total Revenue (USD Million) (2018-2019)
Table 58. Intezyne, Inc SWOT Analysis
Table 59. Intezyne, Inc Neuroendocrine Tumor Drug Product and Services
Table 60. Intezyne, Inc Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 61. Karyopharm Therapeutics, Inc. Basic Information, Manufacturing Base and Competitors
Table 62. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Major Business
Table 63. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Total Revenue (USD Million) (2018-2019)
Table 64. Karyopharm Therapeutics, Inc. SWOT Analysis
Table 65. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product and Services
Table 66. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 67. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 68. Novartis AG Neuroendocrine Tumor Drug Major Business
Table 69. Novartis AG Neuroendocrine Tumor Drug Total Revenue (USD Million) (2018-2019)
Table 70. Novartis AG SWOT Analysis
Table 71. Novartis AG Neuroendocrine Tumor Drug Product and Services
Table 72. Novartis AG Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 73. Midatech Pharma Plc . Basic Information, Manufacturing Base and Competitors
Table 74. Midatech Pharma Plc . Neuroendocrine Tumor Drug Major Business
Table 75. Midatech Pharma Plc . Neuroendocrine Tumor Drug Total Revenue (USD Million) (2018-2019)
Table 76. Midatech Pharma Plc . SWOT Analysis
Table 77. Midatech Pharma Plc . Neuroendocrine Tumor Drug Product and Services
Table 78. Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 79. OctreoPharm Sciences GmbH Basic Information, Manufacturing Base and Competitors
Table 80. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Major Business
Table 81. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Total Revenue (USD Million) (2018-2019)
Table 82. OctreoPharm Sciences GmbH SWOT Analysis
Table 83. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product and Services
Table 84. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 85. Northwest Biotherapeutics, Inc. Basic Information, Manufacturing Base and Competitors
Table 86. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Major Business
Table 87. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Total Revenue (USD Million) (2018-2019)
Table 88. Northwest Biotherapeutics, Inc. SWOT Analysis
Table 89. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product and Services
Table 90. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 91. Millennium Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 92. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Major Business
Table 93. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Total Revenue (USD Million) (2018-2019)
Table 94. Millennium Pharmaceuticals, Inc. SWOT Analysis
Table 95. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product and Services
Table 96. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 97. OXiGENE, Inc. Basic Information, Manufacturing Base and Competitors
Table 98. OXiGENE, Inc. Neuroendocrine Tumor Drug Major Business
Table 99. OXiGENE, Inc. Neuroendocrine Tumor Drug Total Revenue (USD Million) (2018-2019)
Table 100. OXiGENE, Inc. SWOT Analysis
Table 101. OXiGENE, Inc. Neuroendocrine Tumor Drug Product and Services
Table 102. OXiGENE, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 103. MolMed S.p.A. Basic Information, Manufacturing Base and Competitors
Table 104. MolMed S.p.A. Neuroendocrine Tumor Drug Major Business
Table 105. MolMed S.p.A. Neuroendocrine Tumor Drug Total Revenue (USD Million) (2018-2019)
Table 106. MolMed S.p.A. SWOT Analysis
Table 107. MolMed S.p.A. Neuroendocrine Tumor Drug Product and Services
Table 108. MolMed S.p.A. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 109. Global Neuroendocrine Tumor Drug Sales by Manufacturer (2018-2019) (K Pcs)
Table 110. Global Neuroendocrine Tumor Drug Revenue by Manufacturer (2018-2019) (USD Million)
Table 111. Global Neuroendocrine Tumor Drug Sales by Regions (2015-2020) (K Pcs)
Table 112. Global Neuroendocrine Tumor Drug Sales Market Share by Regions (2015-2020)
Table 113. Global Neuroendocrine Tumor Drug Revenue by Regions (2015-2020) (USD Million)
Table 114. North America Neuroendocrine Tumor Drug Sales by Countries (2015-2020) (K Pcs)
Table 115. North America Neuroendocrine Tumor Drug Sales Market Share by Countries (2015-2020)
Table 116. North America Neuroendocrine Tumor Drug Revenue by Countries (2015-2020) (USD Million)
Table 117. North America Neuroendocrine Tumor Drug Revenue Market Share by Countries (2015-2020)
Table 118. Europe Neuroendocrine Tumor Drug Sales by Countries (2015-2020) (K Pcs)
Table 119. Europe Neuroendocrine Tumor Drug Sales Market Share by Countries (2015-2020)
Table 120. Europe Neuroendocrine Tumor Drug Revenue by Countries (2015-2020) (USD Million)
Table 121. Asia-Pacific Neuroendocrine Tumor Drug Sales by Regions (2015-2020) (K Pcs)
Table 122. Asia-Pacific Neuroendocrine Tumor Drug Sales Market Share by Regions (2015-2020)
Table 123. Asia-Pacific Neuroendocrine Tumor Drug Revenue by Regions (2015-2020) (USD Million)
Table 124. South America Neuroendocrine Tumor Drug Sales by Countries (2015-2020) (K Pcs)
Table 125. South America Neuroendocrine Tumor Drug Sales Market Share by Countries (2015-2020)
Table 126. South America Neuroendocrine Tumor Drug Revenue by Countries (2015-2020) (USD Million)
Table 127. South America Neuroendocrine Tumor Drug Revenue Market Share by Countries (2015-2020)
Table 128. Middle East & Africa Neuroendocrine Tumor Drug Sales by Countries (2015-2020) (K Pcs)
Table 129. Middle East & Africa Neuroendocrine Tumor Drug Sales Market Share by Countries (2015-2020)
Table 130. Middle East & Africa Neuroendocrine Tumor Drug Revenue by Countries (2015-2020) (USD Million)
Table 131. Middle East & Africa Neuroendocrine Tumor Drug Revenue Market Share by Countries (2015-2020)
Table 132. Global Neuroendocrine Tumor Drug Sales by Type (2015-2020) (K Pcs)
Table 133. Global Neuroendocrine Tumor Drug Sales Share by Type (2015-2020)
Table 134. Global Neuroendocrine Tumor Drug Revenue by Type (2015-2020) (USD Million)
Table 135. Global Neuroendocrine Tumor Drug Revenue Share by Type (2015-2020)
Table 136. Global Neuroendocrine Tumor Drug Sales by Application (2015-2020) (K Pcs)
Table 137. Global Neuroendocrine Tumor Drug Sales Share by Application (2015-2020)
Table 138. Global Neuroendocrine Tumor Drug Sales Forecast by Regions (2021-2025) (K Pcs)
Table 139. Global Neuroendocrine Tumor Drug Market Share Forecast by Regions (2021-2025)
Table 140. Global Neuroendocrine Tumor Drug Sales Forecast by Type (2021-2025) (K Pcs)
Table 141. Global Neuroendocrine Tumor Drug Market Share Forecast by Type (2021-2025)
Table 142. Global Neuroendocrine Tumor Drug Sales Forecast by Application (2021-2025)
Table 143. Global Neuroendocrine Tumor Drug Market Share Forecast by Application (2021-2025)
Table 144. Direct Channel Pros & Cons
Table 145. Indirect Channel Pros & Cons
Table 146. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Neuroendocrine Tumor Drug Picture
Figure 2. Global Sales Market Share of Neuroendocrine Tumor Drug by Type in 2019
Figure 3. mTOR protein inhibitors Picture
Figure 4. Tyrosine kinase 3 inhibitors Picture
Figure 5. Somatostatin receptor antagonists Picture
Figure 6. Growth hormone releasing factor antagonists Picture
Figure 7. Somatostatin receptor agonists Picture
Figure 8. Others Picture
Figure 9. Neuroendocrine Tumor Drug Sales Market Share by Application in 2018
Figure 10. Hospital Picture
Figure 11. Clinic Picture
Figure 12. Others Picture
Figure 13. Global Neuroendocrine Tumor Drug Market Status and Outlook (2015-2025) (USD Million)
Figure 14. United States Neuroendocrine Tumor Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 15. Canada Neuroendocrine Tumor Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Mexico Neuroendocrine Tumor Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Germany Neuroendocrine Tumor Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 18. France Neuroendocrine Tumor Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 19. UK Neuroendocrine Tumor Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Russia Neuroendocrine Tumor Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Italy Neuroendocrine Tumor Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 22. China Neuroendocrine Tumor Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Japan Neuroendocrine Tumor Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Korea Neuroendocrine Tumor Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 25. India Neuroendocrine Tumor Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Southeast Asia Neuroendocrine Tumor Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Australia Neuroendocrine Tumor Drug Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 28. Brazil Neuroendocrine Tumor Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Egypt Neuroendocrine Tumor Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Saudi Arabia Neuroendocrine Tumor Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 31. South Africa Neuroendocrine Tumor Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 32. Turkey Neuroendocrine Tumor Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 33. Global Neuroendocrine Tumor Drug Sales Market Share by Manufacturer in 2019
Figure 34. Global Neuroendocrine Tumor Drug Revenue Market Share by Manufacturer in 2019
Figure 35. Top 3 Neuroendocrine Tumor Drug Manufacturer (Revenue) Market Share in 2019
Figure 36. Top 6 Neuroendocrine Tumor Drug Manufacturer (Revenue) Market Share in 2019
Figure 37. Key Manufacturer Market Share Trend
Figure 38. Global Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 39. Global Neuroendocrine Tumor Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 40. Global Neuroendocrine Tumor Drug Revenue Market Share by Regions (2015-2020)
Figure 41. Global Neuroendocrine Tumor Drug Revenue Market Share by Regions in 2018
Figure 42. North America Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
Figure 43. Europe Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
Figure 44. Asia-Pacific Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
Figure 45. South America Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
Figure 46. Middle East & Africa Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020)
Figure 47. North America Neuroendocrine Tumor Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 48. North America Neuroendocrine Tumor Drug Sales Market Share by Countries (2015-2020)
Figure 49. North America Neuroendocrine Tumor Drug Sales Market Share by Countries in 2018
Figure 50. North America Neuroendocrine Tumor Drug Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 51. North America Neuroendocrine Tumor Drug Revenue Market Share by Countries in 2018
Figure 52. United States Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 53. Canada Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 54. Mexico Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 55. Europe Neuroendocrine Tumor Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 56. Europe Neuroendocrine Tumor Drug Revenue Market Share by Countries (2015-2020)
Figure 57. Europe Neuroendocrine Tumor Drug Revenue Market Share by Countries in 2019
Figure 58. Germany Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 59. UK Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 60. France Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 61. Russia Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 62. Italy Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 63. Asia-Pacific Neuroendocrine Tumor Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 64. Asia-Pacific Neuroendocrine Tumor Drug Sales Market Share by Regions 2019
Figure 65. Asia-Pacific Neuroendocrine Tumor Drug Revenue Market Share by Regions 2019
Figure 66. China Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 67. Japan Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 68. Korea Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 69. India Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 70. Southeast Asia Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 71. South America Neuroendocrine Tumor Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 72. South America Neuroendocrine Tumor Drug Sales Market Share by Countries in 2019
Figure 73. South America Neuroendocrine Tumor Drug Revenue Market Share by Countries in 2019
Figure 74. Brazil Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 75. Argentina Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 76. Middle East and Africa Neuroendocrine Tumor Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 77. Middle East and Africa Neuroendocrine Tumor Drug Sales Market Share by Countries in 2019
Figure 78. Middle East and Africa Neuroendocrine Tumor Drug Revenue Market Share by Countries (2015-2020)
Figure 79. Middle East and Africa Neuroendocrine Tumor Drug Revenue Market Share by Countries in 2019
Figure 80. Saudi Arabia Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 81. Egypt Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 82. Turkey Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 83. South Africa Neuroendocrine Tumor Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 84. Global Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2025) (K Pcs)
Figure 85. Global Neuroendocrine Tumor Drug Revenue and Growth Rate (2021-2025) (USD Million)
Figure 86. North America Sales Neuroendocrine Tumor Drug Market Forecast (2021-2025) (K Pcs)
Figure 87. Europe Sales Neuroendocrine Tumor Drug Market Forecast (2021-2025) (K Pcs)
Figure 88. Asia-Pacific Sales Neuroendocrine Tumor Drug Market Forecast (2021-2025) (K Pcs)
Figure 89. South America Sales Neuroendocrine Tumor Drug Market Forecast (2021-2025) (K Pcs)
Figure 90. Middle East & Africa Sales Neuroendocrine Tumor Drug Market Forecast (2021-2025) (K Pcs)
Figure 91. Sales Channel: Direct Channel vs Indirect Channel
腫瘍壊死因子阻害薬の世界市場 2020年 Market Overview The global Tumor Necrosis Factor Inhibitors Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Tumor N…- ソマトスタチン受容体4型の世界市場 2020年 Market Overview The global Somatostatin Receptor Type 4 market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Somatostatin Rec…
- 腫瘍壊死因子受容体スーパーファミリーメンバー9の世界市場 2020年 Market Overview The global Tumor Necrosis Factor Receptor Superfamily Member 9 market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 201…
- チロシンプロテインキナーゼ受容体TYRO3の世界市場 2020年 Market Overview The global Tyrosine Protein Kinase Receptor TYRO3 market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Tyrosi…
- チロシンキナーゼ阻害剤の世界市場 2020年 Market Overview The global Tyrosine Kinase Inhibitors market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Tyrosine Kinase In…